Decreased average TSPO binding levels posttreatment correlate with slower progression of motor symptoms, adding to the evidence that TSPO levels can be used as a dynamic biomarker of therapeutic efficacy in ALS [94]. The gene discussed is TSPO; the disease is amyotrophic lateral sclerosis.